COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Tanvex BioPharma USA, Inc. Achieves Dual U.S. Regulatory Milestones: FDA Approves Nypozi(TM) and FDA Accepts Biosimilar Biologics License Application for TX-05
Tanvex BioPharma USA, Inc. receives FDA approval for NYPOZI™ biosimilar and FDA BLA acceptance for TX-05, showcasing expertise in biologics development and manufacturing -
-
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
NanoViricides, Inc. provides update on Phase II clinical trial plans for broad-spectrum antiviral drug candidate NV-387 against RSV, COVID, and Influenza. Potential $12 Billion market. Novel trial design expected -
COMMUNIQUÉ DE PRESSE
SXG Extends High-Grade Mineralisation 150 m Down Dip at Rising Sun West
Mawson Gold Limited reports high-grade gold and antimony intersections at Sunday Creek Project in Victoria, Australia. Assay results from drill holes SDDSC122 and SDDSC122W1 revealed significant mineralization -
-
-
